Cargando…
INCIDENCE OF COVID-19 INFECTIONS IN ADULTS WITH PRIMARY IMMUNODEFICIENCY AFTER RECEIVING TIXAGEVIMAB AND CILGAVIMAB
INTRODUCTION: Individuals with a primary immunodeficiency are at an increased risk of developing SARS-CoV-2 infection. Tixagevimab and cilgavimab is a neutralizing long-acting monoclonal antibody that has been shown to prevent SARS-CoV-2 infection. However, there has been limited data on the efficac...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646423/ http://dx.doi.org/10.1016/j.anai.2022.08.652 |